Hillel Bachrach, Jason Camm and Zafrira Avnur join EnClear Therapies Board of Directors Investors include 20/20 HealthCare Partners, Amgen Ventures, Peter Thiel, Global Health Sciences (GHS) Fund, Christian Angermayer’s Presight… Read More
Company Anticipates Earlier Than Expected Preliminary Data Readout in August 2020 SAN DIEGO, Feb. 19, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on… Read More
Commenced Dosing of Patients in Phase 1 Clinical Trial with INM-755 Vancouver, BC – February 14, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage… Read More
“We are pleased with the pace of progress of both trials, which in some cases have enrolled patients faster than our previous forecasts. We are seeing rapid progress with encouraging… Read More
VANCOUVER, British Columbia, Feb. 11, 2020 (GLOBE NEWSWIRE) — Quark Venture LP and GF Securities today announced that they have contributed to the $12 million seed financing to launch Volastra… Read More
